Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Anglo American

(Sharecast News) - Analysts at Berenberg lowered their target price on mining giant Anglo American from 2,100.0p to 2,000.0p on Monday, noting that it saw "better value elsewhere" in the space. Berenberg updated its model following Anglo American's FY24 results, with the shares having outperformed since the release as the market reacted positively to a better net debt balance, driven mainly by positive working capital flows and an agreement with Codelco to enter into a joint mine plan for the Los Bronces and Andina mines in Chile.

"The revised mine plan, which is expected to take effect from 2030 and will need revised permits, will lead to higher-grade ore from Andina filling latent processing capacity at Los Bronces, lifting volumes by c120ktpa (100%) and reducing costs by c15%, releasing, in Anglo's view, at least $5.0bn of value," said Berenberg.

The German bank said this was a good example of the sort of value creation that it thinks should be executed more by mining companies, and said "the pressure is now on" for Anglo, Glencore and Teck Resources to agree a similar deal on the Collahuasi and QB2 mines, also in Chile. However, Berenberg stated this will need "all partners to be on the same page".

"We update our model for the results and guidance. We also add in extra conservatism for De Beers and make some more conservative assumptions on cost savings, which are key drivers of our softer EPS in 2026. We lift our EV/EBITDA multiple to 6x from 5.5x; our price target trims to 2,000.0p per share. Anglo is trading on 6.9x 2025E EBITDA and 1.52x NAV; we see better value in Rio Tinto (trading on 0.84x NAV and 5.6x 2025E EBITDA)," said Berenberg, which reiterated its 'sell' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.